FDG PETNCT07506447
The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma
An observational study of FDG PET and Mucosal Melanoma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
This project will target patients with histopathologically diagnosed mucosal melanoma using [¹⁸F]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of [¹⁸F]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- FDG PET, Mucosal Melanoma
- What is being tested?
- Telephone follow-up
- How many people
- 68 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2021to 13 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We reviewed the electronic medical record and imaging data of patients with pathologically confirmed mucosal melanoma who underwent [18F]FDG PET/CT imaging at the PET Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 1, 2021 and June 1, 2024.
Who may be able to join
- Patients with histopathologically confirmed mucosal melanoma.
Who cannot join
- Having another primary malignancy (other than mucosal melanoma).
- Being lost to follow-up.
- Being under 18 years of age.
- Being pregnant or breastfeeding.
Trial locations and contacts
1 site in 1 country.
About this study
This project will target patients with histopathologically diagnosed mucosal melanoma using [¹⁸F]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of [¹⁸F]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations between quantitative [¹⁸F]FDG PET parameters and progression-free survival (PFS) as well as overall survival (OS), so as to provide reference evidence for individualized treatment decision-making.
- Conditions
- FDG PET, Mucosal Melanoma
- Being tested
- Telephone follow-up
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Telephone follow-upOther
Telephone follow-up
| Study group | Role | What they receive |
|---|---|---|
| Mucosal Melanoma Cohort | Retrospective cohort of mucosal melanoma patients who underwent [18F]FDG PET/CT for prognostic evaluation. Receives: Other: Telephone follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Overall survival (OS) is defined as the time elapsed from the date of the ¹⁸F-FDG PET/CT examination to the date of death.
Measured: Up to 4 years
Progression-free survival
Progression-free survival (PFS) is defined as the time from the date of [18F]FDG PET/CT imaging to the earliest date of disease progression, recurrence, or death.
Measured: Up to 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2026
- Study start1 Jan 2021
- Primary completion8 May 2025
- Study completion13 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FDG PETStudies of the same condition, open and under way.
- More trials run by Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07506447
- Sponsor's protocol ID
- XLan-251264
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 1 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma
- ClinicalTrials.gov ID
- NCT07506447
- Acronym / sponsor ID
- XLan-251264
- Conditions
- FDG PET, Mucosal Melanoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 8 May 2025 (actual)
- Study completion
- 13 Mar 2026 (actual)
- First posted
- 1 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project will target patients with histopathologically diagnosed mucosal melanoma using [¹⁸F]FDG PET/CT imaging for retrospective prognostic evaluation.The primary objective is to explore the value of [¹⁸F]FDG PET/CT imaging in the prognostic assessment of mucosal melanoma, and to determine the correlations between quantitative [¹⁸F]FDG PET parameters and progression-free survival (PFS) as well as overall survival (OS), so as to provide reference evidence for individualized treatment decision-making.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mucosal Melanoma Cohort | – | Other: Telephone follow-upRetrospective cohort of mucosal melanoma patients who underwent [18F]FDG PET/CT for prognostic evaluation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We reviewed the electronic medical record and imaging data of patients with pathologically confirmed mucosal melanoma who underwent [18F]FDG PET/CT imaging at the PET Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 1, 2021 and June 1, 2024.
Key inclusion criteria (1 listed)
- Patients with histopathologically confirmed mucosal melanoma.
Key exclusion criteria (4 listed)
- Having another primary malignancy (other than mucosal melanoma).
- Being lost to follow-up.
- Being under 18 years of age.
- Being pregnant or breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Telephone follow-upTelephone follow-up | Other | Mucosal Melanoma Cohort |
Primary outcome
Overall survival
Time frame: Up to 4 years
Overall survival (OS) is defined as the time elapsed from the date of the ¹⁸F-FDG PET/CT examination to the date of death.
Progression-free survival
Time frame: Up to 4 years
Progression-free survival (PFS) is defined as the time from the date of [18F]FDG PET/CT imaging to the earliest date of disease progression, recurrence, or death.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for FDG PET
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Active, not recruitingObservational study
Whole-Body ⁶⁸Ga-FAPI PET/CT in Cavernous Sinus Syndrome: A Prospective Comparison With ¹⁸F-FDG PET/CT
Cavernous Sinus Syndrome
RecruitingPhase 2
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
HIV
RecruitingPhase 4
Assessment of the Value of FAPI and FDG-PET-CT in Diagnosis of Acute Phase Peyronie's Disease
Peyronie's Disease
RecruitingPhase 3
Pericardial Imaging Study
Pericarditis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of FDG PET and Mucosal Melanoma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: Up to 4 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.